SCHEMBL22228697

SCHEMBL22228697

Cc1ccc2ncc(-c3nc(Cl)ncc3F)n2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 5/20 0.44
NRAS P01111 1/20 0.44
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
GAA P10253 2/20 0.37
TP53 P04637 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
RAB9A P51151 1/20 0.36
HPGD P15428 1/20 0.36
EIF2AK4 Q9P2K8 1/20 0.36
IGF1R P08069 1/20 0.35
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
GLA P06280 1/20 0.34
NR1H4 Q96RI1 1/20 0.34
CYP11B1 P15538 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3310129 0.86 FLT3 (0.43) FLT3NRASEIF2AK4IGF1RPRMT5
SCHEMBL28705227 0.84 PIK3CA (0.47) FLT3NRASGAAMAPTSMN1; SMN2
SCHEMBL29544366 0.84 PIK3CA (0.47) FLT3NRASGAAMAPTSMN1; SMN2
SCHEMBL20455687 0.82 EIF2AK4 (0.52) FLT3NRASEIF2AK4
SCHEMBL22252951 0.81 FLT3 (0.38) FLT3NRASCYP1A2CYP2C9GAA
SCHEMBL20455535 0.81 FLT3 (0.44) FLT3NRASMAPTPRMT5WDR77
SCHEMBL3314099 0.78 FLT3 (0.42) FLT3NRASEIF2AK4IGF1RCYP11B1
SCHEMBL700990 0.78 FLT3 (0.52) FLT3MAPTRAB9AIGF1RPIK3CA
SCHEMBL20455515 0.78 FLT3 (0.40) FLT3NRASGAATP53POLB
SCHEMBL3315522 0.75 IGF1R (0.44) FLT3NRASIGF1RPRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398132-B2 Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents AUCENTRA THERAPEUTICS PTY LTD (AU) 2025-08-26 US disclosed
EP-3577116-B1 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-A]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS CHANGZHOU QIANHONG BIO PHARMA CO LTD (CN) 2025-04-23 EP disclosed
CN-114269742-B Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amine as therapeutic agents 常州千红生化制药股份有限公司 2024-07-16 CN disclosed
US-20220259203-A1 DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2022-08-18 US disclosed
EP-3997088-A1 DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS Aucentra Therapeutics Pty Ltd (AU) 2022-05-18 EP disclosed
CN-114269742-A Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amines as therapeutic agents 常州千红生化制药股份有限公司 2022-04-01 CN disclosed
CN-110418789-B Derivatives of N-cycloalkyl/heterocycloalkyl-4- (imidazo [1,2-a ] pyridine) pyrimidin-2-amines as therapeutic agents 常州千红生化制药股份有限公司 2022-03-25 CN disclosed
US-11111245-B2 Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents AUCENTRA THERAPEUTICS PTY LTD (AU) 2021-09-07 US disclosed
WO-2021003517-A1 DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2021-01-14 WO disclosed
US-20200231586-A1 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2020-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220259203-A1 DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS FLT3, CDK2, CDK4 FLT3 1/4885NRAS 160/4885CYP1A2 2626/4885
US-20200231586-A1 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS CDK2, CDKL1, CDKL2 FLT3 282/4885NRAS 946/4885CYP1A2 2153/4885
US-12398132-B2 Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents FLT3, CDK2, CDK4 FLT3 1/4885NRAS 161/4885CYP1A2 2526/4885
US-11111245-B2 Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents CDK2, CDKL1, CDKL2 FLT3 282/4885NRAS 946/4885CYP1A2 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.